Russia approves new state strategy for pharmaceutical industry

18 September 2018


A new state strategy for the development of the domestic pharmaceutical industry, known as "Strategy for the development of the pharmaceutical industry of Russia until 2030," has been recently approved by the Russian Ministry of Industry and Trade, with the aim to bring the Russian pharmaceutical production to a new level.

At the heart of the new strategy is increasing the domestic production of innovative drugs and the beginning of their massive exports to abroad, primarily to emerging nations of Asia-Pacific, Latin America and Eastern Europe, reports The Pharma Letter’s local correspondent.

According to an official spokesman for Russian Minister of Health Veronika Skvorstsova, in recent years the quality of domestically-produced drugs has significantly improved, while the range has become more diversified. At the same time, in addition to common drugs, the production of vaccines has also increased.

According to Ms Skvortsova’s spokesman, drug exports out of Russia are also being considered by some global pharmaceutical companies operating production facilities within Russia.

Due to the devaluation of the Russian currency – the rouble - that has been observed in recent years, drug exports out of Russia has become more profitable to producers than supplies to the domestic market.

Finally, the new strategy involves the production of active substances in Russia which, in turn, should create conditions for the establishment of drug production, starting from zero.




Read more


Read more

Media Center

Read more